Compare Mondaycom Ltd (MNDY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Sana Biotechnology Inc — how do they compare? Mondaycom Ltd trades at $81.4 (market cap $3.53B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Mondaycom Ltd is far larger — about 3.4× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| MNDY | SANA | |
|---|---|---|
Market Cap | $3.53B | $1.03B |
Sector | Technology | Health |
52-Week High | $219.15 | $5.92 |
52-Week Low | $58.81 | $2.68 |
Enterprise Value | $2.70B | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNDY trades at $83.67, down 8.13% over 24 hours amid a bearish technical signal, though it holds above key support at $82. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.48 actual versus $1.11 expected, and maintains robust revenue growth, with 2025 revenue at $1.23 billion. Analyst sentiment remains positive with a consensus buy rating and a $106 price target, reflecting confidence in its enterprise software growth and AI monetization.
The outlook for MNDY is cautiously optimistic, supported by consistent earnings beats and high gross margins of 88.74%, but risks include heightened competition in SaaS and potential volatility from its elevated P/E ratio of 35.4. The stock's current dip may present a buying opportunity for growth-oriented investors, contingent on sustained execution and market conditions.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
